AKT1 and hepatocellular carcinoma: Direct evidence has also revealed that activation of the PI3K/Akt/HIF-1α pathway plays a critical role in mediating hypoxia-induced drug resistance resulting in an unfavorable treatment outcome of hepatocellular carcinoma (31).